Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PRODIGE 33 - BALLAD - Phase III Trial Investigating the Potential Benefit of Adjvant Chemotherapy for Small Bowel Adenocarcinoma

NCT02502370 is registered in ClinicalTrials.gov with Centre Hospitalier Universitaire Dijon as lead sponsor.

NCT NCT02502370
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02502370 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PRODIGE 33 - BALLAD - Phase III Trial Investigating the Potential Benefit of Adjvant Chemotherapy for Small Bowel Adenocarcinoma
Lead sponsor
Centre Hospitalier Universitaire Dijon
Phase
Phase 3
Overall status
Unknown status
Start date
Not reported
Completion date
Not reported
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adjuvant chemotherapy for sba, small bowel adenocarcinoma